Summary of results obtained with immunoblot analyses using TTP patient plasma
. | . | Anti-ADAMTS13 inhibitor titer, BU/mL . | . | ADAMTS13 fragments, prokaryotic . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | ADAMTS13 activity, % . | . | rADAMTS13, eukaryotic . | Propeptide . | tsp1-1 . | cat/dis/tsp1-1 . | cys-rich/spacer . | tsp1/2-8 . | cub1+2 . | |||||
| 1 | ≈6 | 3 | + | − | − | − | + | − | − | |||||
| 2 | < 5 | 3 | + | − | − | + | + | − | + | |||||
| 3 | < 3 | 3 | + | − | − | − | + | − | − | |||||
| 4 | < 3 | 8 | + | − | − | − | + | − | + | |||||
| 5 | < 3 | 9 | + | − | − | − | + | − | − | |||||
| 6 | 3-5 | 8 | + | − | − | − | + | − | + | |||||
| 7 | < 3 | 6 | + | − | + | + | + | + | + | |||||
| 8 | < 3 | 1 | + | − | − | − | + | + | + | |||||
| 9 | < 3 | 10 | + | − | − | − | + | − | + | |||||
| 10 | < 5 | 40 | + | + | + | + | + | + | + | |||||
| 11 | < 6 | 16 | + | − | − | + | + | + | + | |||||
| 12 | < 6 | 2 | + | − | + | + | + | − | + | |||||
| 13 | < 6 | 8 | + | − | + | + | + | − | + | |||||
| 14 | < 6 | 32 | + | − | + | + | + | − | + | |||||
| 15 | < 6 | 18 | + | − | − | + | + | − | − | |||||
| 16 | 9 | 1 | + | − | + | + | + | − | − | |||||
| 17 | < 6 | 1 | + | − | + | + | + | − | + | |||||
| 18 | < 6 | 6 | + | + | + | + | + | − | + | |||||
| 19 | < 6 | 4 | + | − | − | + | + | − | + | |||||
| 20 | < 6 | 4 | + | − | + | + | + | − | − | |||||
| 21 | < 6 | 2 | + | − | + | + | + | + | − | |||||
| 22 | < 6 | 10 | + | + | + | − | + | − | − | |||||
| 23 | 10 | 2 | + | + | + | − | + | − | − | |||||
| 24 | 10 | 2 | + | + | + | − | + | + | + | |||||
| 25 | < 6 | 5 | + | − | + | − | + | + | + | |||||
| Total patients | − | − | 25/25 | 5/25 | 14/25 | 14/25 | 25/25 | 7/25 | 16/25 | |||||
| Percentage | − | − | 100 | 20 | 56 | 56 | 100 | 28 | 64 | |||||
. | . | Anti-ADAMTS13 inhibitor titer, BU/mL . | . | ADAMTS13 fragments, prokaryotic . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | ADAMTS13 activity, % . | . | rADAMTS13, eukaryotic . | Propeptide . | tsp1-1 . | cat/dis/tsp1-1 . | cys-rich/spacer . | tsp1/2-8 . | cub1+2 . | |||||
| 1 | ≈6 | 3 | + | − | − | − | + | − | − | |||||
| 2 | < 5 | 3 | + | − | − | + | + | − | + | |||||
| 3 | < 3 | 3 | + | − | − | − | + | − | − | |||||
| 4 | < 3 | 8 | + | − | − | − | + | − | + | |||||
| 5 | < 3 | 9 | + | − | − | − | + | − | − | |||||
| 6 | 3-5 | 8 | + | − | − | − | + | − | + | |||||
| 7 | < 3 | 6 | + | − | + | + | + | + | + | |||||
| 8 | < 3 | 1 | + | − | − | − | + | + | + | |||||
| 9 | < 3 | 10 | + | − | − | − | + | − | + | |||||
| 10 | < 5 | 40 | + | + | + | + | + | + | + | |||||
| 11 | < 6 | 16 | + | − | − | + | + | + | + | |||||
| 12 | < 6 | 2 | + | − | + | + | + | − | + | |||||
| 13 | < 6 | 8 | + | − | + | + | + | − | + | |||||
| 14 | < 6 | 32 | + | − | + | + | + | − | + | |||||
| 15 | < 6 | 18 | + | − | − | + | + | − | − | |||||
| 16 | 9 | 1 | + | − | + | + | + | − | − | |||||
| 17 | < 6 | 1 | + | − | + | + | + | − | + | |||||
| 18 | < 6 | 6 | + | + | + | + | + | − | + | |||||
| 19 | < 6 | 4 | + | − | − | + | + | − | + | |||||
| 20 | < 6 | 4 | + | − | + | + | + | − | − | |||||
| 21 | < 6 | 2 | + | − | + | + | + | + | − | |||||
| 22 | < 6 | 10 | + | + | + | − | + | − | − | |||||
| 23 | 10 | 2 | + | + | + | − | + | − | − | |||||
| 24 | 10 | 2 | + | + | + | − | + | + | + | |||||
| 25 | < 6 | 5 | + | − | + | − | + | + | + | |||||
| Total patients | − | − | 25/25 | 5/25 | 14/25 | 14/25 | 25/25 | 7/25 | 16/25 | |||||
| Percentage | − | − | 100 | 20 | 56 | 56 | 100 | 28 | 64 | |||||
Plus signs denote positive reactivity toward the respective ADAMTS13 fragments; and—, no signal detected.